Jaktinib Hydrochloride Cream For Atopic Dermatitis

• Status: Recruiting
• Trial end date: 2022-12-01

Summary

This study includes a dose escalation part and a dose extension part.

• Phase: Phase 1/Phase 2

Details

• Lead Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd